In:
Oncology, S. Karger AG, Vol. 91, No. 6 ( 2016), p. 302-310
Kurzfassung:
〈 b 〉 〈 i 〉 Objective: 〈 /i 〉 〈 /b 〉 To assess the immunosuppressive effect of R-CHOP in patients with B-cell lymphoma at 2 years. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Parameters of humoral and cell-mediated immunity were assessed in 89 patients with diffuse large B-cell lymphoma or follicular lymphoma before and after 6-8 cycles of R-CHOP-14 or R-CHOP-21 regimen. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Data on pre- and posttreatment serum IgG (sIgG) levels were available for all 89 patients, while the corresponding data on serum CD20+, CD3+, CD4+, and CD8+ lymphocyte counts were available in only 43. Median sIgG levels significantly decreased from 1,221 mg/dl (baseline) to 733 mg/dl (after chemotherapy) (p 〈 0.001). Although CD20+ and CD4+ cell counts decreased (p 〈 0.001), no significant effect of chemotherapy on CD3+ and CD8+ cell counts was observed. CD20+ cell counts were restored to baseline levels at the 12-month follow-up. sIgG levels and CD4+ cell counts were not completely restored at 24 months, indicating a sustained immunosuppressive effect of R-CHOP in these patients. The incidence of infections over the 2-year period was 16.3-23.6%. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 The immunosuppressive effect of R-CHOP in newly diagnosed cases of B-cell lymphoma tends to persist for 〉 2 years, although sIgG levels were restored more quickly than CD4+ cell counts.
Materialart:
Online-Ressource
ISSN:
0030-2414
,
1423-0232
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2016
ZDB Id:
1483096-6
ZDB Id:
250101-6
